Skip to main content

2027 QPP Final Rule: What’s Changing and Why It Matters

US Capitol

CMS released the 2027 Medicare Physician Fee Schedule (PFS) final rule on November 4, 2026. The final rule sunsets traditional MIPS after the 2030 performance period, two years later than CMS proposed in July, giving clinicians a firm timeline for the long-anticipated transition to MIPS Value Pathways (MVPs). It also finalizes changes to quality reporting, the Promoting Interoperability performance category, and Advanced APM participation. Most policies were finalized as proposed. This post summarizes what CMS finalized and how it affects future reporting requirements.

We’ve already published a detailed breakdown of the proposed changes specific to Medicare Shared Savings Program (MSSP) ACOs. This post covers the broader MIPS and Quality Payment Program (QPP) provisions affecting clinicians, groups, and Advanced APM participants.

MIPS Value Pathways: The Future Arrives in 2031

Traditional MIPS Is Being Phased Out

CMS has signaled for several years that traditional MIPS reporting would eventually end. The final rule establishes a formal timeline for that transition. CMS proposed ending traditional MIPS after the 2028 performance period but finalized a two-year delay. Traditional MIPS will remain available through the 2030 performance period. Starting with the 2031 performance period, MVPs will be the only MIPS reporting option for clinicians who do not participate in a MIPS Alternative Payment Model (APM). Clinicians in a MIPS APM will continue to have the option to report through the APM Performance Pathway (APP) or APP Plus, as applicable.

Why This Matters: The countdown is now real. Clinicians have four performance years, 2027 through 2030, to identify the MVP most relevant to their specialty, build workflows to collect the required data, and establish subgroup-level reporting processes, if needed. Practices that wait until 2031 to prepare may face significant operational and reporting challenges.

Three New MVPs Finalized for 2027

CMS finalized three new MVPs for the 2027 performance period, bringing the total to 30 MVPs:

  • Diabetic Disease
  • Hypertension
  • Hospitalist

The Diabetic Disease and Hypertension MVPs reflect CMS’s stated focus on prevention and chronic disease management—conditions that, when managed proactively, can significantly reduce downstream costs and health care utilization for Medicare patients. The Hospitalist MVP addresses a specialty that plays a critical role in care coordination and the cost and quality of care delivered to hospitalized patients.

Why This Matters: Clinicians in primary care, internal medicine, and hospital medicine now have additional MVP options to evaluate. If your practice has been holding off because no MVP felt like a good fit, the new Diabetic Disease and Hypertension MVPs, in particular, are worth a close look.

Changes to All 27 Existing MVPs

CMS finalized modifications to all 27 previously finalized MVPs, including:

  • Adding MIPS core measure selections to each MVP to support the new MIPS core measure reporting requirement
  • Adding measures that expand clinical concepts or capture additional specialties applicable to a given MVP
  • Removing measures and activities finalized for removal from their respective MIPS inventories or replacing them with more robust alternatives

CMS also renamed the Rehabilitative Support for Musculoskeletal Care MVP as the Rehabilitative Support MVP, better reflecting the broader scope of measures and activities it includes.

Virtual Groups Can Begin Reporting MVPs in 2029

Under current policy, virtual groups cannot report an MVP. CMS finalized a change that allows virtual groups to report an MVP beginning with the 2029 performance period.

Why This Matters: Virtual groups that currently report traditional MIPS can choose between traditional MIPS and an MVP in 2029 and 2030. Because MVPs become the only option in 2031, virtual groups should begin evaluating MVP options well before then.

Quality Performance Category: Significant Changes Ahead

A New MIPS Core Measure Requirement

One of the more substantive structural changes in the final rule is the introduction of a MIPS core measure designation. CMS finalized this designation for 77 measures for the 2027 performance period.

The core measure requirement replaces the existing requirement that clinicians report at least one outcome measure, or a high-priority measure when an applicable outcome measure is unavailable. Beginning with the 2027 performance period:

  • Traditional MIPS reporters are required to report one MIPS core measure as one of their six required quality measures.
  • MVP reporters are required to report one MIPS core measure as one of their four required quality measures.
  • Small practices are exempt from this requirement.

Traditional MIPS reporters can select an applicable core measure from the broader MIPS quality measure inventory or an applicable specialty measure set. MVP reporters select a core measure included in their chosen MVP.

If a clinician or reporting entity does not have an applicable MIPS core measure available to report, the clinician or entity must attest to that fact and report another measure in its place. Clinicians who do not report a core measure, do not qualify for the small practice exemption, and do not complete the required attestation and replacement reporting will receive 0 out of 10 points for one of their required quality measures.

Why This Matters: Clinicians should review their current measure set against the final MIPS core measure list. If none of their six reported measures carry the MIPS core measure designation—and they are not a small practice—they’ll need to either add one or attest that no applicable core measure is available and report another measure in its place. Ignoring this requirement could result in a zero for one required quality measure.

CMS Eliminates the High-Priority Measure Designation

To align with the shift to core measures, CMS finalized the removal of the high-priority measure designation from the MIPS quality measure inventory and the MVP inventory. CMS also eliminated the requirement that MIPS eligible clinicians report at least one outcome measure, or a high-priority measure if no applicable outcome measure is available. The high-priority designation previously helped satisfy that reporting requirement and was one factor CMS considered when deciding whether to retain a measure. Both of those functions have been eliminated.

Quality Measure Inventory Changes

CMS finalized a total of 180 quality measures for the 2027 performance period, down from 190 in 2026. These totals exclude QCDR measures, which CMS approves outside the rulemaking process. Key changes to the inventory include:

  • Addition of 2 new quality measures focused on prevention and chronic disease management, one of which is delayed until 2028
  • Adoption of 4 current QCDR measures as MIPS CQMs
  • Replacement of 7 existing functional improvement MIPS measures with 5 new functional outcome measures for orthopedic patients, which were QCDR measures and are now finalized as MIPS CQMs
  • Removal of 20 quality measures from the inventory
  • Substantive changes to 43 existing quality measures

The tables below list the new measures and the measures finalized for removal.

New Quality Measures Finalized for the 2027 Performance Period
Quality ID Measure Title Collection Type
Q517Low Density Lipoprotein Cholesterol (LDL-C) Monitoring and ManagementMIPS CQM
Q518Functional Improvement for Patients with Neck ImpairmentsMIPS CQM
Q519Functional Improvement for Patients with Upper Extremity ImpairmentsMIPS CQM
Q520Functional Improvement for Patients with Back ImpairmentsMIPS CQM
Q521Functional Improvement for Patients with Lower Extremity ImpairmentsMIPS CQM
Q522Functional Improvement for Patients with Knee ImpairmentsMIPS CQM
Q523Age-Related Hearing Loss: Comprehensive Audiometric EvaluationMIPS CQM
Q524Patient-Reported Experience with AnesthesiaMIPS CQM
Q525Intraoperative Hypotension (IOH) Among Non-Emergent Noncardiac Surgical CasesMIPS CQM
Q526SGLT2 Inhibitors for Patients with Chronic Kidney Disease (CKD) With or Without Type 2 Diabetes MellitusMIPS CQM

The five new functional outcome measures for orthopedic patients (neck, back, upper extremity, lower extremity, and knee) are based on the PROMIS® framework and are finalized as MIPS CQMs to replace seven older FOTO-based functional status change measures removed from the inventory.

Looking Ahead to 2028: CMS finalized a one-year implementation delay for the new Rate of Timely Follow-up on Abnormal Screening Mammograms for Breast Cancer Detection eCQM (Q527). The measure will become available beginning with the 2028 performance period.

Quality Measures Finalized for Removal in the 2027 Performance Period
Quality IDMeasure TitleRationale
006Coronary Artery Disease (CAD): Antiplatelet TherapyNo longer maintained by measure steward
007Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior MI or LVEF ≤ 40%No longer maintained by measure steward
143

Oncology: Medical and Radiation—Pain Intensity Quantified

End of topped-out lifecle
217

Functional Status Change for Patients with Knee Impairments

Duplicative of new measure
218

Functional Status Change for Patients with Hip Impairments

Duplicative of new measure
219Functional Status Change for Patients with Lower Leg, Foot or Ankle ImpairmentsDuplicative of new measure
220Functional Status Change for Patients with Low Back ImpairmentsDuplicative of new measure
221Functional Status Change for Patients with Shoulder ImpairmentsDuplicative of new measure
222Functional Status Change for Patients with Elbow, Wrist or Hand ImpairmentsDuplicative of new measure
320Appropriate Follow-Up Interval for Normal Colonoscopy in Average-Risk PatientsEnd of topped-out lifecycle
326Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation TherapyNo longer maintained by measure steward
332Adult Sinusitis: Appropriate Choice of Antibiotic—Amoxicillin With or Without ClavulanateDuplicative of existing measure (Q331)
350Total Knee or Hip Replacement: Shared Decision-Making: Trial of Conservative TherapyProcess measure
378Children Who Have Dental Decay or CavitiesMeasure robustness concerns
384Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to OR Within 90 DaysEnd of topped-out lifecycle
415Emergency Department Utilization of CT for Minor Blunt Head Trauma (18+)End of topped-out lifecycle
430Prevention of Post-Operative Nausea and Vomiting (PONV)—Combination TherapyEnd of topped-out lifecycle
463Prevention of Post-Operative Vomiting (POV)—Combination Therapy (Pediatrics)End of topped-out lifecycle
478Functional Status Change for Patients with Neck ImpairmentsDuplicative of new measure
483Person-Centered Primary Care Measure Patient-Reported Outcome Performance MeasureLimited adoption; benchmark cannot be created

Why This Matters: Clinicians currently reporting any of the measures on the removal list will need to identify replacements for the 2027 performance period. Review the new measures closely. Several specialties, including orthopedics, cardiology, nephrology, anesthesiology, and audiology, gain new options that may be a better fit than what they report today.

Scoring Relief for Topped-Out Core Measures

CMS finalized the application of the previously defined topped-out measure benchmarks to 15 quality measures for the 2027 performance period, including two measures that do not currently receive these benchmarks. CMS will now publish this list on the QPP website instead of in the Federal Register.

CMS also finalized that topped-out MIPS core measures subject to the 7-point scoring cap will no longer be capped at 7 points. Beginning with 2027, these measures will instead be scored according to the defined topped-out measure benchmark, with a maximum of 10 points.

Why This Matters: Clinicians who consistently perform at or near 100% on a topped-out measure that receives the MIPS core designation and is currently subject to the 7-point cap could see a meaningful increase in their quality score. However, the number of points earned would still depend on the clinician's performance rate under the defined benchmark.

The MIPS Performance Threshold Remains at 75 Points

CMS previously finalized a 75-point MIPS performance threshold through the 2028 performance period. The final rule does not change that threshold for 2027.

Why This Matters: A final MIPS score of at least 75 points will continue to be required to avoid a negative payment adjustment. However, changes to quality measure selection and scoring could affect how clinicians reach that threshold.

Promoting Interoperability: Fewer Requirements and New Prior Authorization Measures

Changes to the Definition of CEHRT

CMS finalized an update to the definition of Certified Electronic Health Record Technology (CEHRT) to align with certification criteria removed under the HTI-5 final rule. The change is primarily technical and does not immediately alter clinicians’ reporting responsibilities.

CMS Removes Two ONC Attestations

CMS finalized the removal of two ONC-related attestations from the Promoting Interoperability (PI) performance category:

  • The ONC Direct Review attestation, which was required
  • The ONC-Authorized Certification Body (ONC-ACB) Surveillance attestation, which was optional

Both are removed beginning with the 2026 performance period, so clinicians reporting 2026 data during the 2027 submission period will not complete these attestations.

Why This Matters: This means fewer PI requirements during the next submission cycle. Remove both attestations from 2026 data before submitting. CMS will reject file upload and API submissions that still include either attestation.

Security Risk Analysis Measure Removed in 2027

The Security Risk Analysis measure, long a required element of the PI category, is removed starting with the 2027 performance period.

Why This Matters: This eliminates one required PI measure beginning with the 2027 performance period. Importantly, the change applies only to the MIPS PI measure. It does not eliminate separate security risk analysis obligations that may apply under HIPAA.

Electronic Prior Authorization: Optional in 2027, Required in 2028

The Electronic Prior Authorization measure has a more complex trajectory under the final rule. It had previously been finalized as a required PI measure starting with 2027. Under the final rule, CMS will:

  • Make it an optional bonus measure worth 10 bonus points for 2027 rather than a required measure
  • Require it beginning in 2028
  • Require clinicians who choose to report the measure in 2027 to use specified FHIR-enabled, ONC-certified health IT modules within CEHRT
  • Beginning in 2028, require CEHRT to include health IT modules certified to all three ONC electronic prior authorization criteria

CMS also finalized a new measure, Electronic Prior Authorization for Prescription Drugs, which becomes required starting with the 2028 performance period. This measure requires the use of specified FHIR-enabled health IT modules within CEHRT to complete at least one prior authorization request for prescription drugs or medications.

Why This Matters: Clinicians and practices have one more year before electronic prior authorization becomes mandatory under the Promoting Interoperability performance category. The 2027 performance year provides additional time to confirm that EHR technology supports the required FHIR-enabled modules for both medical services and prescription drugs. Organizations planning to report the optional medical services measure for bonus credit in 2027 should also confirm that their technology meets the requirements.

Improvement Activities: Six Additions and 11 Removals Finalized

CMS finalized the following changes to the Improvement Activities inventory for the 2027 performance period:

  • Addition of 6 new activities
  • Modification of 5 existing activities
  • Removal of 11 activities

New Improvement Activities for 2027

CMS finalized the following six new Improvement Activities:

  • Use of Data to Improve Practice Workflows
  • Understand and Improve Diagnostic Performance
  • Systematic Screening and Intervention for Nutrition and Other Health-Impacting, Non-Clinical Issues
  • Advance Care Planning Conversations to Support Patient Wellness and Care Preferences
  • Clinician Use of Artificial Intelligence (AI) to Improve Patient Care
  • Lifestyle Approaches to Diabetes Remediation

The new activities address care coordination, diagnostic safety, nutrition and other nonclinical needs, advance care planning, responsible use of artificial intelligence, and lifestyle-based diabetes management.

Improvement Activities Removed in 2027

CMS finalized the removal of the following 11 Improvement Activities:

  • IA_BE_15: Engagement of Patients, Family, and Caregivers in Developing a Plan of Care
  • IA_BMH_5: MDD Prevention and Treatment Interventions
  • IA_CC_10: Care Transition Documentation Practice Improvements
  • IA_CC_11: Care Transition Standard Operational Improvements
  • IA_CC_12: Care Coordination Agreements That Promote Improvements in Patient Tracking Across Settings
  • IA_CC_16: Primary Care Physician and Behavioral Health Bilateral Electronic Exchange of Information for Shared Patients
  • IA_EPA_4: Additional Improvements in Access as a Result of QIN/QIO Technical Assistance
  • IA_PM_2: Anticoagulant Management Improvements
  • IA_PM_19: Glycemic Screening Services
  • IA_PM_20: Glycemic Referring Services
  • IA_PSPA_2: Participation in MOC Part IV

Why This Matters: The additions give clinicians new options aligned with emerging priorities such as responsible AI use, diagnostic safety, nutrition, and chronic disease management. Clinicians currently reporting one of the 11 removed activities will need to select an alternative Improvement Activity for the 2027 performance period.

Cost Performance Category: No Major Changes

The Cost category is largely unchanged in the final rule. CMS finalized no new cost measures and no removals for the 2027 performance period. The only update is a non-substantive maintenance revision to the operational list of care episode and patient condition groups and codes, which CMS is required to update annually under statute.

Why This Matters: No new cost measure preparation is required for 2027. That said, cost continues to carry a 30% weight in MIPS scoring for traditional MIPS reporters, so performance on existing measures remains consequential.

Advanced APMs: QP Determinations Move to the TIN/NPI Level

A More Targeted Approach to QP Status

Under current policy, Qualifying APM Participant (QP) determinations are made at the NPI level—meaning that when a clinician achieves QP status, the financial incentives and MIPS exemption apply across every TIN under which the clinician bills, including practices that may not participate in an Advanced APM.

CMS finalized, with modification, a policy applying QP and Partial QP determinations at the TIN/NPI level beginning with the 2027 QP performance period. QP status, including its financial incentives and MIPS exemption, will apply only to the TIN/NPI combinations participating in an Advanced APM. In a change from the proposal, CMS will extend Partial QP status to all TIN/NPI combinations for clinicians who achieve QP or Partial QP status through individual determinations. Partial QPs can choose whether to participate in MIPS.

Why This Matters: Clinicians who bill under multiple TINs—only some of which participate in an Advanced APM—should evaluate how this change could affect their MIPS obligations. QP status no longer automatically extends to every TIN under which the clinician bills.

Changes to QP and Partial QP Thresholds

As a result of the Consolidated Appropriations Act, 2026, CMS finalized temporarily lower the thresholds used to determine QP and Partial QP status for the 2026 performance year:

  • QP thresholds decrease from 75% to 50% under the payment amount method and from 50% to 35% under the patient count method.
  • Partial QP thresholds decrease from 50% to 40% under the payment amount method and from 35% to 25% under the patient count method.

The higher thresholds return beginning with the 2027 performance year.

Why This Matters: Clinicians who may not meet the higher thresholds in 2025 could have an easier path to QP or Partial QP status in 2026. However, organizations should prepare for the higher thresholds to return in 2027.

Additional MSSP ACO Quality Reporting Policies

The final rule also includes several quality reporting policies specific to MSSP ACOs, including the continued availability of MIPS CQM reporting, an extension of the MIPS CQM reporting incentive, flat benchmarks for Medicare CQMs, a new Medicare eCQM collection type based on assigned beneficiaries, and revised CEHRT requirements.

For a breakdown of the ACO proposals, see our companion post: 2027 Medicare Physician Fee Schedule Proposed Rule: Major Changes for MSSP ACOs.

Preparing for the Next Phase of MIPS

The 2027 final rule represents one of the most significant changes to the MIPS program since its inception. For years, clinicians have known traditional MIPS would eventually end. Now CMS has set a date. The 2030 performance period will be the last year traditional MIPS is available, and practices that haven’t started evaluating MVPs should start now.

Beyond the MVP transition, the shift to MIPS core measures, the phased rollout of electronic prior authorization requirements, and the simplification of the Promoting Interoperability category all point toward a program with more standardized reporting expectations and a greater emphasis on prevention, interoperability, and clinically meaningful measures.

Clinicians and organizations should review the final rule and current CMS guidance as they plan for the 2027 performance period.